GlassScriptPhysician profile
Beth A Knox
NPI 1831424266
$2,274.11
in general payments reported to CMS, 2019-2025
23 companies · $602 in 2025
The $602 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.47 · 2022: $150 · 2023: $676 · 2024: $793 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,071.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $671.33 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $297.28 | 2022-2024 | Mounjaro, Trulicity, Jardiance |
| Abbott Laboratories | $162.88 | 2021-2025 | Freestyle Libre |
| Novo Nordisk INC | $129.57 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $128.22 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $127.21 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Pfizer INC. | $111.57 | 2023-2024 | |
| Globus Medical, INC. | $80.83 | 2025 | Senza |
| Dexcom, INC. | $72.14 | 2021-2024 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.88 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.15 | 2023-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $56.44 | 2022-2023 | Seglentis, Livalo |
| Astellas Pharma US INC | $51.38 | 2024-2025 | Veozah |
| Mylan Specialty L.P. | $46.94 | 2022-2023 | Yupelri |
| Axsome Therapeutics, INC. | $36.19 | 2024-2025 | Auvelity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $35.62 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.34 | 2024 | Xifaxan |
| Aimmune Therapeutics, INC. | $19.83 | 2025 | Zenpep |
| Viatris Specialty LLC | $18.38 | 2025 | Yupelri |
| Idorsia Pharmaceuticals US INC | $17.48 | 2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $16.67 | 2023 | Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $15.40 | 2023 | |
| Amgen INC. | $13.38 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Knox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.